Minastrin 24 Fe is an oral contraceptive or birth control medication.
Description of Minastrin 24 Fe
Minastrin 24 Fe (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) contain a progestin, an estrogen, norethindrone acetate, and ethinyl estradiol. This medication works by causing changes in your cervical mucus and uterine lining, which makes it difficult for sperm to get to the uterus. It also makes it harder for a fertilized egg to attach to the uterus. Ethinyl estradiol and norethindrone are used as contraception to prevent pregnancy.
Minastrin 24 Fe provides an oral contraceptive regimen consisting of 24 yellow active soft gelatin capsules that contain the vibrant components, followed by four maroon non-hormonal placebo soft gelatin capsules as specified below:
- 24 transparent, oval, pale yellow capsules with each containing 1 mg norethindrone acetate and 20 mcgethinyl estradiol.
- 4 ovals, opaque, maroon, capsules each containing 75 mg Ferrous fumarate
Side Effects of Minastrin 24 Fe
The side effects of Minastrin 24 Fe may be severe or mild and also depends on other medications the subject might be taking. If any of these effects persist or worsen, talk to your healthcare provider or pharmacist promptly. These adverse reactions include:
Nausea, breast tenderness, vomiting, headache, bloating, swelling of the ankles/feet (fluid retention), or weight change may occur. Some women may witness vaginal bleeding between periods (spotting) or irregular/missed periods, especially during the first few months of initiating. If you miss 2 consecutive periods (or 1 period considering that the pill has not been used properly), contact your healthcare provider a pregnancy test.
- Inform your doctor at once if you notice any serious side effects of Minastrin Fe, including: Mental/mood changes (such as new/worsening depression)
- Lumps in the breast,
- Severe stomach/abdominal pain,
- Yellowing eyes/skin, D
- ark urine, and
- Unusual changes in vaginal bleeding (like as continuous spotting, missed periods, sudden heavy bleeding).
Other rear, but severe adverse reactions associated with Minastrin Fe. In such a situation, you should immediately reach for an immediate help. These conditions consist of:
- Blood clots (such as deep vein thrombosis, pulmonary embolism, and heart attack),
- Chest/jaw/left arm pain, slurred speech, sudden shortness of breath/rapid breathing, sudden dizziness/fainting, confusion, pain/swelling/warmth in the groin/calf,
- Unusual headaches (such as headaches with vision changes/lack of coordination, sudden/very severe headaches, worsening of migraines)
- Unusual sweating
- Vision problems/changes (like as partial/complete blindness, and double vision).
- Weakness on one side of the body
Some other side effects associated with Minastrin Fe have been reported following post marketing experience. These side effects of Manastrin Fe can be enumerated grouped into system organ classes:
i) Vascular disorders: thrombosis/embolism (coronary artery, pulmonary, cerebral, deep vein) shows Minastrin Fe side effects.
ii) Hepatobiliary disorders: hepatic adenoma, hemangioma, cholecystitis, cholelithiasisof liver
iii) Immune system disorders: hypersensitivity reaction.
iv) Skin and subcutaneous disorders: rash, alopecia (generalized and allergic), skin discoloration, pruritus,
v) GI disorders: nausea, vomiting, abdominal pain indicates side effects Minastrin.
vi) Musculoskeletal and connective tissue disorders: myalgia.
vii) Eye disorders: corneal thinning, visual impairment, change in corneal curvature (steepening), and blurred vision,
viii) Infections and infestations: fungal infection, vaginal infection all depicts Minastrin side effects.
ix) Investigations: change in weight or appetite (decrease or increase), peripheral edema, malaise, fatigue, blood pressure increased.
x) Nervous system disorders: migraine, dizziness, headache, loss of consciousness all projects the side effects of Minastrin 24 Fe.
Who should not take Minastrin 24 Fe
Your healthcare coach will not provide you Minastrin 24 Fe if you have:
i) Ever had blood clots in your arms, legs (deep vein thrombosis), lungs (pulmonary embolism), or eyes (retinal thrombosis)
ii) Ever had a stroke
iii) Ever had a heart attack
iv) Certain heart valve problems or heart rhythm abnormalities that can cause blood clots to form in the heart
v) An inherited problem with your blood that makes it clot more than normal
vi) High blood pressure that medicine cannot control
vii) Diabetes with nerve, eye, blood vessel or kidney damage
viii) Ever had certain kinds of severe migraine headaches with numbness,aura, have any migraine headaches if you are over age 35 or changes or weakness in vision,
ix) Ever had breast cancer or any cancer that is sensitive to female hormones
x) Liver disease, including liver tumors
Also, do not take birth control pills if you:
i) Smoke and are over 35 years old
ii) Are or suspect you are pregnant
iii) Have any unexplained bleeding from the vagina
Birth control pills may not be a good choice for you if you have ever had jaundice (yellowing of the skin or eyes) caused by pregnancy, also called cholestasis of pregnancy. Tell your healthcare provider if you have ever had any of the above conditions (your healthcare provider may recommend another method of birth control).
Minastrin 24 Fe: Warnings and Precautions
Minastrin 24 Fe uses could easily be embraced upon, however it is of almost important to start by looking at the warnings and precautions. Minastrin 24 Fe should be fully understood in the area of warnings and precautions before attempting to take. This is very important because as much as Minastrin 24 Fe uses could be good, taking it without considering these warnings and precautions can endanger your life.
i).Thromboembolic Disorders and Other Vascular Problems
- Stop Minastrin 24 Fe if an arterial or deep venous thrombotic event (VTE) takes place.
- Stop taking Minastrin 24 Fe if there is an unexplained loss of diplopia, proptosis, vision, retinal or papilledema vascular lesions. Assess for retinal vein thrombosis immediately.
- If feasible, stop Minastrin 24 Fe at least 4 weeks before and through 2 weeks after major surgery or other surgeries known to have an elevated risk of VTE.
- Start Minastrin 24 Fe no earlier than 4 weeks after childbirth, in women who are not involved in breastfeeding. The danger of postpartum VTE reduces after the third postpartum week, meanwhile the risk of ovulation accelerates after the third postpartum week.
The use of COCs (Combined Oral Contraceptives) increases the danger of VTE (venous thromboembolism) which is a blood clot that starts in a vein. However, pregnancy raises the danger of VTE as much or more than the application of COCs. The danger of VTE in women applying COCs is three to nine per ten thousand women per year. The danger of VTE is at its peak during the first year of use of a COC. The danger of thromboembolic disease as a result to oral contraceptives gradually disappears after COC use is discontinued. Use of COCs also increases the risk of arterial thrombosis such as strokes and myocardial infarctions, most pertaining in women with other danger vectors for these events. COCs have been known to accelerate both the relative and attributable risks of cerebrovascular events (hemorrhagic strokes and thrombotic), even though, generally, the danger is highest in older people less than 35 years of age), hypertensive women who equally takes tobacco. COCs equally raise the danger of stroke in women with underlying risk factors.Use COCs with caution in women with cardiovascular disease risk factors like:
Liver Disease: Do not use Minastrin 24 Fe in women with acute viral hepatitis or severe (decompensated) cirrhosis of the liver. Acute or chronic disruptions of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation have been kept aside. Discontinue the use of Minastrin 24 Fe if jaundice developed.
Liver Tumors: Minastrin 24 Fe is contraindicated in women with benign and malignant liver tumors. Hepatic adenomas are associated with COC use. An estimate of the linkable danger is 3.3 cases per one hundred thousand COC subscribers. A fusion of hepatic adenomas may cause death through intra-abdominal hemorrhage. Studies have shown an increased risk of developing hepatocellular carcinoma in long-term greater than 8 years COC subscribers. By and large, the linkable danger of liver cancers in COC subscribers or users is less than one case per million users.
ii).High Blood Pressure:
Minastrin 24 Fe is contraindicated in women with uncontrolled hypertension or hypertension with vascular ailment. For ladies with well-managed hypertension, survey blood pressure and put off Minastrin 24 Fe if the blood pressure rises significantly. An increase in blood pressure has been reported in women taking COCs, and this risk is more likely to occur in aged women with an extended timeline of use. The situation of hypertension heightens with increasing concentrations of progestin.
iii). Gallbladder Disease:
Studies suggest a small increased relative risk of developing gall bladder disease between COC subscribers. Applying COCs may equally intensify already gall bladder ailment. A past account of COC-associated cholestasis predicts an increased risk with future COC use. Women with a history of pregnancy-associated cholestasis may be at an increased risk for COC-related cholestasis.
iv). Carbohydrate and Lipid Metabolic Effects:
Carefully monitor prediabetic and diabetic women who are taking Minastrin 24 Fe. COCs may reduce glucose management in a dose-related manner. Consider alternative contraception for women with uncontrolled dyslipidemias. A minute fraction of women will have adverse lipid changes while on COCs. Women with a family history or hypertriglyceridemia thereof could be at an increased risk of pancreatitis when using COCs.
If a woman taking Minastrin 24 Fe develops new headaches that are persistent or severe, recurrent, evaluate the cause and discontinue Minastrin 24 Fe if indicated. Consider discontinuation of Minastrin 24 Fe in the case of increased frequency or severity of migraine during COC use (which may be prodromal of a cerebrovascular event)
vi). Bleeding Irregularities and Amenorrhea:
Unscheduled bleeding and spotting: Unscheduled (breakthrough or intra-cyclic) bleeding and spotting sometimes occur in those affected by COCs, particularly during the first quarter use. If bleeding occurs or persists after past regular cycles, look for causes such as malignancy or pregnancy. If pregnancy and pathology are laid off, bleeding disorders may be handled over time or with a change to a different COC based on patient history.
Amenorrhea and Oligomenorrhea: Women who are not pregnant and use Minastrin 24 Fe may witness amenorrhea (a condition in which there is an absence of menstrual periods in a woman). Some women may witness oligomenorrhea (having light or infrequent menstrual periods) or post-pill amenorrhea, particularly when such a situation was pre-existent. If withdrawal (scheduled) bleeding does not manifest, consider the likelihood of pregnancy. If the person affected has not abided to the ordered dose schedule (missed one or more active capsule or started taking them on a day later than she would have), consider the likelihood of pregnancy at the time of the first missed period and take appropriate diagnostic counseling. If the patient has accepted to the ordered regimen and misses two non-stop periods, eliminate out pregnancy.
vii). COC (Combined Oral Contraceptives)use before or during early pregnancy:
Extensive epidemiologic studies have revealed no increased risk of birth defects in women who have used oral contraceptives prior to pregnancy. Studies equally do not attempt a teratogenic impact, especially as cardiac anomalies and limb reduction defects are concerned, with oral contraceptives taken unconsciously during early pregnancy. Stop the use Minastrin 24 Fe if pregnancy is confirmed. Administration of oral contraceptives to induce withdrawal bleeding should not be used as a test for pregnancy.
Carefully examine women with a past track record of depression and discontinue Minastrin 24 Fe if depression recurs to a serious degree.
ix). Carcinoma of the Breast and Cervix:
Minastrin 24 Fe is contraindicated in women who currently have or have had breast cancer because breast cancer may be hormonally-sensitive. There is substantial evidence that COCs do not increase the incidence of breast cancer. Even though some previous studies have postulated that COCs might increase the incidence of breast cancer, more updated studies have not admitted such investigations. Some studies suggest that COCs are associated with an increase in the risk of cervical cancer or intraepithelial neoplasia. By and large, there is friction concerning the extent to which these findings may be due to differences in sexual behavior and other factors.
x). Effect on Binding Globulins:
The estrogen component of COCs may raise the serum concentrations of cortisol-binding globulin, sex hormone-binding and globulin thyroxine-binding globulin. Thus, the dose of replacing cortisol therapy or thyroid hormone may need to be increased.
Minastrin 24 Fe: Dosage of Minastrin 24 Fe
i). How to take Minastrin 24 Fe
To achieve maximum contraceptive capacity, Minastrin 24 Fe has to be administered accordingly as directed by your doctor or healthcare provider. Instruct patients to take a dosage of Minastrin 24 Fe capsule by mouth at the same time each day. Capsules must be taken in the order directed on the blister pack. Capsules must not be taken or skipped at intervals exceeding 24 hours. Minastrin 24 Fe may be administered without regard to meals. Talk to your doctor for any advice with respect to your specific need.
ii). Advice on taking Minastrin 24 Fe
Instruct the patient to begin taking Minastrin 24 Fe either on the first day of her menstrual period (Day 1 Start) or on the first Sunday after the onset of her menstrual period (Sunday Start). Day 1 Start during the first cycle of Minastrin 24 Fe use, a patients may be instructed to take one yellow Minastrin 24 Fe capsule daily, commencing on day one (1) of her menstrual cycle (the first day of menstruation is the first day). She may therefore be required to administer one yellow Minastrin 24 Fe capsule daily for 24 non-stop days, accompany by one maroon capsule daily on days 25 to 28. Minastrin 24 Fe should be administered following the instruction found on the package at the same time each day or as prescribed by your doctor. Healthcare providers should instruct those affected to apply a non-hormonal contraceptive as back-up during the first 7 days (if she starts taking Minastrin 24 Fe on a day other than the first day of her menstrual cycle). The likelihood of conception and ovulation prior to initiation of medication should be considered. The patient should begin her next and all subsequent 28-day regimens of Minastrin 24 Fe on the same day of the week that she began her first regimen, accompanying the same agenda. She should therefore begin taking her yellow capsules on the next day after ingestion of the last maroon capsule, irrespective of whether or not a menstrual period is still in progress or has happened. Whenever a future cycle of Minastrin 24 Fe is started later than the day following administration of the last maroon capsule, those affected should apply another method of contraception until she has taken a yellow Minastrin 24 Fe capsule daily for 7 consecutive days. For postpartum women who do not breastfeed or after a second quarterly abortion, begin Minastrin 24 Fe no earlier than one month postpartum due to the increased risk of thromboembolism. Minastrin 24 Fe may be initiated immediately after a first-trimester abortion or miscarriage; if the patient starts Minastrin 24 Fe rapidly; further contraceptive tips are not needed. Always talk with your healthcare provider in case of any doubt.
iii). Switching from another Hormonal Method of Contraception:
If the patient is switching from a combination hormonal method such as: another pill, vaginal ring, and patch, in such a situation, instruct her to take the first yellow capsule on the day she would have taken her subsequent COC pill. She should not continue consuming the tablet from her previous birth manage pack, and should not miss any days among packs. If she does not experience a retrieving bleed, put off pregnancy before commencing Minastrin 24 Fe. If she previously used a transdermal patch orvaginal ring she should begin applying Minastrin 24 Fe on the day she would have resumed the previous product. If the patient is switching from a progestin-only method such as a progestin-only pill, implant, intrauterine system, and injection, she may switch any day from a progestin-only pill. Instruct the individual to take the first yellow capsule on the day she would have taken her next progestin-only pill. She should apply a non-hormonal approach of contraception for 7 consecutive days. If switching from an injection or implant,begin the first yellow capsule on the day her next injection would have been due or on the day of removal of her implant. If switching from an IUD, depending on the period of taking it off, back-up contraception may be required.
Minastrin 24 Fe: Dosage Forms and Strengths
Dosage of Minastrin 24 Fe in its forms and strength is available in blister packs. Every blister pack consists of 28 soft gelatin capsules in the following order:
- 24 transparent, oval, pale yellow, (active) capsules imprinted with “WC” on one side and each containing 1 mg norethindrone acetate and 20 mcg ethinyl estradiol.
- 4 oval, opaque, maroon, (non-hormonal placebo) capsules imprinted with “WC” on one side and each containing 75 mg Ferrous fumarate. The Ferrous fumarate capsules do not operate any therapeutic purpose.
What happens if you miss your dose of Minastrin 24 Fe
Minastrin 24 Fe may not be dangerous if you miss any yellow capsules, particularly if you forget the first, the last or few yellow capsules in a pack. Take the capsule as soon as you recall. Take the next capsule at your normal hour. This implies you may administer two capsules in one day. You do not need to use a back-up birth control method if you have sex. However, seek advice from your doctor before taking any miss dose.
Minastrin 24 Fe: Uses of Minastrin 24 Fe
The uses of Minastrin are applicable in the following categories as shortlisted below:
- Nursing mothers
- Pediatric use
- Geriatric use
- Renal impairment
- Hepatic impairment
The uses of Minastrin 24 Fe in the above mentioned areas are done carefully and sensitively. Your healthcare professional will drill you with regards of Minastrin 24 Fe uses in the areas raised appropriately.
g). Storage conditions
Store at 25º C (77º F); excursions permitted to 15 to 30º C (59 to 86º F). Guard and protect from light. Store blister card in the wallet provided in the cartonwhen not in use.
This article has been able to provide some useful tips and has given you ample insights on the Minastrin 24 Fe (oral contraceptive) that is the uses of Minastrin 24 Fe, dosage of Minastrin 24 Fe, warning and precautions to be considered while taking this drug and possible side effects of Minastrin 24 Fe. Most importantly what you should note is that this article only acts as a guide and should not replace doctor’s prescription. In as much as drugs do treat or manage diseases, the knowledge behind every drug and what it treats or manage is very important before ever attempting going for it. Therefore with the knowledge in this article on Minastring 24 Fe, it is hope you will be able to get good results as you apply it.